Brolucizimab (Beovu)

Beovu (brolucizumab) is covered for neovascular (wet) AMD and the listed compendial off‑label retinal/neovascular indications (diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularization, and choroidal neovascular conditions); uses not listed are not covered. Approval requires administration by or under the supervision of an ophthalmologist via intravitreal injection, documentation of a covered diagnosis and dosing per the recommended regimen (6 mg monthly ×3 then 6 mg every 8–12 weeks), and authorizations are granted for 12 months.

"Neovascular (Wet) Age-related Macular Degeneration (AMD) (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.